CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,099,260 | -31.8% | 2,292,851 | -15.9% | 0.00% | -40.0% |
| Q2 2023 | $92,537,493 | +11.7% | 2,727,306 | +18.4% | 0.01% | 0.0% |
| Q1 2023 | $82,844,558 | -59.4% | 2,302,525 | -49.8% | 0.01% | -16.7% |
| Q4 2022 | $204,260,210 | +129.1% | 4,582,908 | +44.5% | 0.01% | 0.0% |
| Q3 2022 | $89,153,000 | +2.4% | 3,171,578 | -1.8% | 0.01% | +20.0% |
| Q2 2022 | $87,050,000 | -4.7% | 3,228,852 | +20.4% | 0.01% | 0.0% |
| Q1 2022 | $91,374,000 | -0.1% | 2,682,728 | +13.3% | 0.01% | +25.0% |
| Q4 2021 | $91,501,000 | -8.7% | 2,368,040 | +27.5% | 0.00% | -20.0% |
| Q3 2021 | $100,266,000 | +43.2% | 1,857,118 | -11.3% | 0.01% | +25.0% |
| Q2 2021 | $70,031,000 | +81.1% | 2,094,218 | +11.6% | 0.00% | +100.0% |
| Q1 2021 | $38,666,000 | +21.9% | 1,876,977 | +3.7% | 0.00% | 0.0% |
| Q4 2020 | $31,716,000 | +8335.1% | 1,810,260 | +7030.7% | 0.00% | – |
| Q3 2020 | $376,000 | – | 25,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |